Company's Lincoln Technologies Safety Division President
Recognized as an Inspiration in the Life-sciences Industry
WALTHAM, Mass.--(BUSINESS WIRE)--July 23, 2007--Phase Forward
(NASDAQ: PFWD), a leading provider of data management solutions for
clinical trials and drug safety, today announced that Chan Russell,
President of its Lincoln Technologies safety division has been named
to the esteemed PharmaVOICE 100 list. Generated by PharmaVOICE
readers, the list spotlights those individuals who have proven to be
the most inspiring within the life-sciences industry.
"The PharmaVOICE 100 are exemplary individuals who think outside
of the box, who are pioneering new paths to success, and who are
inspiring their colleagues in the industry," said Taren Grom,
Editor-in-chief and Co-founder, PharmaVOICE. "We are extremely pleased
to recognize these 100 individuals who translate industry issues into
opportunities, and who have taken the time to mentor the next
generation of leaders in the life-sciences arena."
Russell draws from more than 20 years of experience during which
time he led the development of major pharmaceutical industry
applications related to clinical data management, laboratory data
analysis, adverse event tracking and reporting and safety signal
detection. In 1999, Russell founded Lincoln Technologies which, by the
time it was acquired by Phase Forward in 2005, had long been
recognized as a market-leading provider of products and services for
strategic pharmacovigilance, clinical trials safety signal detection
and applied data standards.
Today, the Phase Forward Lincoln Technologies safety solutions are
used by pharmaceutical and biotechnology companies in the U.S., Europe
and Japan, as well as regulatory agencies such as the FDA in the U.S.
and the Medicines and Healthcare products Regulatory Agency (MHRA) in
the U.K.
"It is truly an honor to be named to the PharmaVOICE 100 list,"
said Russell. "It brings me much personal and professional
satisfaction to be a part of the Phase Forward Lincoln Technologies
team - a team dedicated to bringing critically needed safety solutions
to market."
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. The company offers
proven solutions for electronic data capture (InForm(TM)), clinical
data management (Clintrial(TM)), clinical trials signal detection
(CTSD(TM)), strategic pharmacovigilance (WebVDME(TM) and Signal
Management), adverse event reporting (Clintrace(TM)) and applied data
standards (WebSDM(TM)). In addition, the company provides services in
the areas of application implementation, hosting and validation, data
integration, business process optimization, safety data management and
industry standards. Phase Forward's products and services have been
utilized in over 10,000 clinical trials involving more than 1,000,000
clinical trial study participants at over 250 organizations and
regulatory agencies worldwide including: AstraZeneca, Boston
Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and
Drug Administration, or FDA, GlaxoSmithKline, Harvard Clinical
Research Institute, Merck & Co., Merck Serono, Novartis, Novo Nordisk,
PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis,
Schering-Plough Research Institute, Servier, Tibotec and the U.K.
Medicines and Healthcare Products Regulatory Agency. Additional
information about Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains express or
implied forward-looking statements relating to Phase Forward's
expectations concerning continued service of its executive personnel.
These statements are neither promises nor guarantees, but are subject
to a variety of risks and uncertainties, many of which are beyond
Phase Forward's control, which could cause actual results to differ
materially from those contemplated in these forward-looking
statements. In particular, the risks and uncertainties include, among
other things, the ability of Phase Forward to retain its executive
personnel. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or circumstances
or otherwise. For additional disclosure regarding these and other
risks faced by Phase Forward, see the disclosure contained in Phase
Forward's public filings with the Securities and Exchange Commission
including, without limitation, its most recent Quarterly Report on
Form 10-Q.
CONTACT: Phase Forward
Gretchen Dock, 781-902-4413
gretchen.dock@phaseforward.com
or
CHEN PR, Inc.
Meghan Locke, 781-672-3147
mlocke@chenpr.com
SOURCE: Phase Forward
